Loading...

COCP COCRYSTAL PHARMA INC US FDA Inspections 8-K Filing

CCRY

CCP

COCRYSTAL PHARMA INC

(COCP)

2026 8-K

FDA Fast Track Approval

Financial Results Update

Director's Passing

Norovirus Announcement

Stock Options Granted

Study Approval Announced

Conference Presentation

Quarterly Results

Securities Purchase Agreement

NIH Grant Award

Funding Announcement

Event Announcement

Stock Offering Announcement

Earnings Results Report

Clinical Trials

Investor Meetings

Management Changes

Investor Meetings

Product Expansion

Financial Statements

New Product Launches

Investor Meetings

Equity Incentive Plan

Auditor Consent Correction

Earnings Announcement

Investor Presentation

Positive Study Results

Study Enrollment Extension

Earnings Announcement

Antiviral Update

Executive Compensation

Investment Conferences

Quarterly Results

Clinical Development Update

Update on CC-42344 product ...

Earnings Reports

Clinical Development Update

Earnings Reports

Clinical Development Update

Termination of License Agre...

Presentation to Investors

Clinical Development Updates

Termination of Agreement

Presentation to Investors

Investor Conferences

Earnings Reports

Phase 2a Trial Authorization

Earnings Reports

Prospectus Supplement Filing

Annual Meeting of Stockholders

Earnings Reports

Appointment of Director

Investment Agreement

Litigation Victory

Disclosure of Interview Tra...

Investor Conferences

External Links:

On April 2, 2026, Cocrystal Pharma, Inc. announced that the FDA granted Fast Track designation to their oral protease inhibitor CDI-988, aimed at treating norovirus infections. This is a significant event for the company, indicating positive progress in their drug development.

AI Assistant

COCRYSTAL PHARMA INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.